NCT04841577View on ClinicalTrials.gov

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

976

Participants

Timeline

Start Date

April 27, 2021

Primary Completion Date

September 22, 2021

Study Completion Date

February 8, 2022

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSVPreF3 OA investigational vaccine

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

BIOLOGICAL

FLU-QIV

FLU-QIV administered intramuscularly in the deltoid region of the dominant (Co-Ad Group) arm or the non-dominant (Control Group) arm.

Trial Locations (14)

1001

GSK Investigational Site, Panama City

1010

GSK Investigational Site, Auckland

1055

GSK Investigational Site, Middelburg

1459

GSK Investigational Site, Boksburg

1701

GSK Investigational Site, Auckland

3001

GSK Investigational Site, Tauranga

4130

GSK Investigational Site, Havelock North

5032

GSK Investigational Site, Paraparaumu

6242

GSK Investigational Site, Wellington

7002

GSK Investigational Site, Panama City

7099

GSK Investigational Site, Panama City

7219

GSK Investigational Site, Panama City

8011

GSK Investigational Site, Christchurch

0801

GSK Investigational Site, Panama City

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04841577 - A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above | Biotech Hunter | Biotech Hunter